In G3 medulloblastoma, autocrine IL6 signaling activates the STAT3 pathway, contributing to drug resistance; thus, targeting the IL6/STAT3 axis has been proposed as a therapeutic strategy for G3 medulloblastoma [58]. This evidence concerns the gene IL6 and medulloblastoma.